The arrival of artificial intelligence in healthcare brings massive opportunities, but it also creates thorny new problems, especially when it comes to liability. With the FDA’s final guidance on Clinical Decision Support (CDS) software now in effect, the way clinicians have to think about AI recommendations has completely changed. Cardiologists and their legal teams now have a critical need to get smart on their professional and legal duties. That guidance, along with new positions from groups like the American Medical Association (AMA), forces a hard look at how we’re using AI-driven cardiac alerts in our workflows and, more importantly, how we document our decisions to either follow or ignore them.
Working through the FDA’s CDS Guidance and its Liability Implications
The FDA has been trying to draw a clear line between software that’s a medical device and software that’s just for clinical decision support. This isn’t just semantics, it directly defines the regulatory oversight and your potential liability. According to the FDA’s January 2026 CDS Guidance, certain software might be considered “non-device CDS” if it just provides recommendations to a professional who can independently review the basis for that recommendation, and as long as it isn’t processing medical images or signals itself FDA September 2022 CDS Guidance. This type of software gets a pass from most FDA medical device rules. The problem is, that line gets blurry fast. When a CDS moves from offering a suggestion to making what looks like an independent diagnosis or driving a treatment without a human really in the loop, it’s a different story. For example, an AI that spits out “HFpEF confirmed” is almost certainly a regulated device. But if it says “probable HFpEF, recommend referral,” it could be a non-device CDS. What does that mean for you? It means the type of AI system you’re using determines its regulatory path (like a 510(k) or De Novo classification) and the liability that comes with it. As a cardiologist, you absolutely must know if the tool in your hands is a regulated SaMD (Software as a Medical Device) or a non-device CDS, because it changes the standard of care you’re expected to provide when you see its output.
Peer-Review Standards and Real-World Evidence for Clinical Reliability
Clinical reliability isn’t optional for any AI tool, no matter what its FDA status is. That means it needs rigorous, peer-reviewed outcome validation to prove it does what it claims to do in a messy, real-world clinical environment. The gold standard for any AI in healthcare is that it must be trained on real patient data, not clean, synthetic, or anonymized datasets that can’t possibly capture the true diversity of our patient populations or how a disease actually presents. You have to use real-world evidence (RWE) to build trust and make sure the tool performs equitably for everyone. Hello Heart is a good example of a company taking this seriously, through their work with the American College of Cardiology (ACC) and a built-in pharmacist-oversight architecture that shows how to integrate AI responsibly. Their published, peer-reviewed studies demonstrate the efficacy and safety of their tools. This kind of setup, with its defined clinical guardrails and an oversight model built to catch errors before a patient is affected, is exactly what the Clinical AI Standards Hub promotes. This level of validation, especially with RWE, makes for a much stronger FDA submission and a better story for payers, which in the end de-risks the whole proposition of bringing the tech into a clinic.
AMA’s Stance on AI Liability and Physician Accountability
The American Medical Association (AMA) has been vocal about AI’s impact on medical liability. The AMA’s policy is clear: AI tools can be great for informing decisions, but the physician keeps the ultimate responsibility for the patient’s care AMA 2023 AI policy resolutions. You can’t just blindly follow an AI’s recommendation without applying your own critical evaluation. The AMA wants policies that spell out liability, making sure that the developers, the health systems, and the end-users are all held accountable for their part. For a cardiologist on the ground, this means your professional judgment is more important than ever. If an AI cardiac alert suggests a specific action, you’re expected to dig into the underlying data, think about the patient’s full clinical picture, and then make a call. If you decide to go against the AI’s suggestion and something goes wrong, your thought process and justification are going to be put under a microscope. The AMA sees AI as a powerful tool for augmenting your expertise, not replacing it.
Actionable Documentation Strategies for Cardiologists
With the liability ground shifting beneath our feet, cardiologists have to get serious about documentation when using AI-driven cardiac alerts. This is absolutely essential when you decide to override an AI’s recommendation. Your clear, concise note is your best defense in a potential lawsuit and proves you’re following federal and professional standards. When you accept an AI recommendation, your documentation should include:
- The specific AI tool you used and what its alert said.
- A note confirming you reviewed the AI’s output and the data it used.
- A short statement that the AI’s suggestion makes clinical sense for this specific patient.
When you override an AI recommendation, you need to be much more thorough:
- Write down exactly what the AI recommended.
- Explain your specific clinical reasons for going against it. Maybe the AI didn’t account for certain comorbidities, or you saw conflicting clinical signs, or new test results came in. Your own expert judgment is a valid reason, too.
- State what you decided to do instead and why.
- Note if you consulted with any colleagues or specialists to make your decision.
This kind of detail does more than just protect you. It creates a data trail that helps improve future AI models, because developers can analyze where and why a human expert’s judgment diverged from the algorithm.
The Hello Heart Model: A Framework for Clinically Validated AI
Hello Heart’s platform is a practical example of how to meet these tough requirements for clinically sound AI. Their system has pharmacist oversight built in, which provides another human check on AI-generated recommendations. Having this human-in-the-loop is a smart way to catch algorithmic drift or strange edge cases where an AI might get it wrong. Because they use real patient training data, their models are strong and can be generalized to wider populations. And it’s not just talk. Hello Heart’s peer-reviewed, published outcomes prove that their tools actually work to improve patient health. Hello Heart published outcomes That kind of transparency and commitment to real evidence is how you build trust with clinicians and patients. For any cardiologist thinking about bringing AI into their practice, looking at a model like Hello Heart’s gives you a concrete playbook for handling the complexities, mitigating your risks through solid validation, and operating with clear oversight. AI is coming to cardiology, and it will be a good thing, but it demands that we get ahead of the liability question. By understanding the FDA’s guidance, insisting on tough validation standards, and being disciplined about our documentation, cardiologists can use these new tools to give better patient care without putting their professional standing at risk. The only way cardiac AI works in the long run is by marrying powerful technology with our own unwavering clinical responsibility.
Frequently Asked Questions
How does the FDA distinguish between different types of AI in healthcare, and why is this distinction important for cardiologists?
The FDA distinguishes between software that functions as a medical device and software that serves purely as clinical decision support (CDS). This distinction is critical because it directly impacts regulatory oversight and potential liability. Cardiologists must be aware of whether an AI tool is a regulated SaMD (Software as a Medical Device) or a non-device CDS, as this influences the standard of care expected when interacting with its outputs.
What is the AMA’s stance on physician accountability when using AI tools for cardiac care?
The AMA emphasizes that while AI tools can enhance clinical decision-making, the ultimate responsibility for patient care remains with the physician. Clinicians cannot simply defer to AI recommendations without independent critical evaluation. The AMA advocates for policies that clarify liability, ensuring developers, providers, and users of AI are held accountable for their respective roles, with physicians maintaining professional judgment.
What kind of evidence is required to establish the clinical reliability of an AI tool, especially for cardiac applications?
Clinical reliability for any AI tool, regardless of FDA classification, necessitates rigorous peer-reviewed outcome validation in real-world clinical settings. This requires real patient training data, not synthetic or anonymized datasets, to ensure equitable performance across diverse patient populations. This commitment to real-world evidence (RWE) is crucial for building trust and de-risking the technology for clinical adoption.
What are the liability implications if an AI system makes an independent diagnostic determination, such as ‘HFpEF confirmed’?
If an AI system makes an independent diagnostic determination, such as ‘HFpEF confirmed,’ it is likely a regulated device. This means it would fall under a specific regulatory pathway (e.g., 510(k) clearance or De Novo classification) and an associated liability framework. The type of AI system dictates its regulatory pathway and the associated liability framework.
